Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | DANUBE: PD-L1 as a predictor of survival in patients with mUC

Joaquim Bellmunt • 28 Sep 2021
ESMO 2021
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Durvalumab Tremelimumab
DANUBE

Joaquim Bellmunt, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, presents an update of the DANUBE study (NCT02516241), evaluating PD-L1 as a predictive marker of immunotherapy benefit in patients with previously untreated metastatic urothelial carcinoma (mUC). The TC/IC25 algorithm is predictive of longer survival in patients treated with durvalumab or durvalumab plus tremelimumab but it is not prognostic; however, PD-L1 expression can play a role in identifying patients with mUC that benefit from immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Joaquim Bellmunt

Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
2:13
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
Joaquim Bellmunt • 30 May 2026
ctDNA-guided therapy: transforming treatment decisions across tumor types
1:20
ctDNA-guided therapy: transforming treatment decisions across tumor types
Joaquim Bellmunt • 30 May 2026
ctDNA in bladder cancer: interpreting results and clinical limitations
1:56
ctDNA in bladder cancer: interpreting results and clinical limitations
Joaquim Bellmunt • 28 Feb 2026
Will ctDNA becoming a routine postoperative risk stratification tool in MIBC?
4:01
Will ctDNA becoming a routine postoperative risk stratification tool in MIBC?
Joaquim Bellmunt • 28 Feb 2026

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals